GGrantIndex
← Leaderboards

Sacha Gnjatic

Icahn School Of Medicine At Mount Sinai

$20,887,220
Attributed
$25,742,243
Total exposure
6
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $13.6M · FY201725
$20M$15M$10M$5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$25,742,243 · 6

By mechanism

U24$19,427,674 · 1
U01$2,881,766 · 1
N02$2,712,342 · 1
P30$720,461 · 3

Most similar at Icahn School Of Medicine At Mount Sinai

Same institution · by research overlap

Others in their field

Other Emerging Leaders on “Immunologist

Research focus

ImmunologistResponseBloodMicrobiomeMalignant NeoplasmsImmuneTranscriptomicsCellsTissuesProteomicsCancer PatientProteinsImmunologic MonitoringImmune Checkpoint BlockadeData SetSamplingHigh DimensionalityPhenotypeFundingCancer ImmunotherapyMolecularImmunotherapy TrialsInnovationLaboratories

Grant awards (16)

High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials$1,992,193
U24 · FY2025 · CA · contact PI
Human Immune Monitoring Center$118,531
P30 · FY2025 · CA · contact PI
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials$1,891,928
U24 · FY2024 · CA · contact PI
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$554,399
U01 · FY2024 · DK · contact PI
Human Immune Monitoring Center$120,386
P30 · FY2024 · CA · contact PI
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials$1,983,570
U24 · FY2023 · CA · contact PI
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$577,498
U01 · FY2023 · DK · contact PI
Human Immune Monitoring Center$120,386
P30 · FY2023 · CA · contact PI
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$577,498
U01 · FY2022 · DK · contact PI
Human Immune Monitoring Center$120,386
P30 · FY2022 · CA · contact PI
CYTOF AND O-LINK ASSESSMENT IN THE `NCI COVID-19 IN CANCER PATIENTS STUDY' (NCCAPS)$2,712,342
N02 · FY2021 · CA · contact PI
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$577,498
U01 · FY2021 · DK · contact PI
Human Immune Monitoring Center$120,386
P30 · FY2021 · CA · contact PI
Characterizing and predicting colitis in immune checkpoint blockade-treated cancer patients$594,873
U01 · FY2020 · DK · contact PI
Human Immune Monitoring Center$120,386
P30 · FY2020 · CA · contact PI
High-Dimensional Immune Monitoring of NCI-Supported Immunotherapy Trials$13,559,983
U24 · FY2017 · CA · contact PI